Title : Prospective Open-label Trial of Early Concomitant Vasopressin and Norepinephrine Therapy versus Initial Norepinephrine Monotherapy in Septic Shock.

Pub. Date : 2018 May

PMID : 29600824






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 This trial was conducted to test the hypothesis that early concomitant treatment with vasopressin and norepinephrine reduces the time to achieve and maintain target MAP compared with initial norepinephrine monotherapy. Norepinephrine arginine vasopressin Homo sapiens
2 Between March and June 2016, vasopressin was initiated within 4 hours of norepinephrine. Norepinephrine arginine vasopressin Homo sapiens
3 Patients treated with early concomitant vasopressin and norepinephrine more frequently had a positive culture (59% vs 37%, p=0.05) and grew nonlactose fermenting gram-negative bacilli (34% vs 10%, p=0.01) compared with patients treated with norepinephrine monotherapy, respectively. Norepinephrine arginine vasopressin Homo sapiens
4 CONCLUSION: Patients treated with early concomitant vasopressin and norepinephrine achieved and maintained MAP of 65 mm Hg faster than those receiving initial norepinephrine monotherapy, suggesting that overcoming vasopressin deficiency sooner may reduce the time patients spend in the early phase of septic shock. Norepinephrine arginine vasopressin Homo sapiens